A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.
Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica RA, Kornblum N, Shah N, Levitz D, Rockwell B, Shapiro LC, Gupta R, Pradhan K, Xue X, Munoz A, Dhawan A, Fehn K, Comas M, Verceles JA, Jonas BA, Kambhampati S, Shi Y, Braunschweig I, Cooper DL, Konopleva M, Feldman EJ, Verma A.
Goldfinger M, et al. Among authors: dhawan a.
Blood. 2024 Nov 28;144(22):2360-2363. doi: 10.1182/blood.2024025834.
Blood. 2024.
PMID: 39316768
Free PMC article.
Clinical Trial.